Exagen Inc
XGN
NASDAQ
Biotechnology
$6.66
USD
+0.08 (+1.22%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $159.21M
Volume 154.2K
Revenue
$71.12M
TTM
+20.8%
YoY
Gross Margin
59%
TTM
-1.3%
YoY
Net Income
$-18.92M
TTM
-11.4%
YoY
Operating Cash Flow
$-6.50M
TTM
+57.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 17.2 | 17.2 | 16.6 | 17.3 | 19.9 |
YoY Growth | +14.2% | +37.9% | +21.8% | +11.7% | +15.9% |
Cost of Revenue | 6.8 | 7.2 | 7.4 | 7.1 | 7.7 |
Gross Profit | 10.4 | 10.1 | 9.2 | 10.2 | 12.2 |
Selling, General & Administrative | 11.5 | 11.4 | 12.4 | 12.1 | 12.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 13.0 | 13.2 | 14.2 | 13.6 | 13.9 |
Operating Income | -2.6 | -3.1 | -5.0 | -3.4 | -1.7 |
EBITDA | -2.2 | -2.5 | -4.4 | -2.8 | -1.1 |
Other Income / Expense | -0.6 | -2.7 | 1.6 | 0.8 | -0.3 |
Total Other Income / Expense | -1.8 | -4.0 | 0.3 | -0.5 | -1.5 |
Income Before Income Taxes | -4.4 | -7.1 | -4.7 | -3.9 | -3.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -4.4 | -7.1 | -4.7 | -4.0 | -3.2 |
Consolidated Net Income / Loss | -4.4 | -7.1 | -4.7 | -4.0 | -3.2 |
Net Income Attributable to Common Shareholders | -4.4 | -7.1 | -4.7 | -4.0 | -3.2 |
Basic EPS | -$0.21 | -$0.31 | -$0.20 | -$0.17 | -$0.13 |
Diluted EPS | -$0.21 | -$0.31 | -$0.20 | -$0.17 | -$0.13 |
Basic Shares Outstanding | 21.1M | 22.9M | 23.6M | 23.9M | 24.2M |
Diluted Shares Outstanding | 21.1M | 22.9M | 23.6M | 23.9M | 24.2M |